

## Prostatic Urethral Lift (PUL)

Last Review Date: November 12, 2021

Number: MG.MM.ME.62d

### Medical Guideline Disclaimer

Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request for prior authorization. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary. If there is a discrepancy between this guideline and a member's benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication. EmblemHealth Services Company LLC, ("EmblemHealth") has adopted the herein policy in providing management, administrative and other services to EmblemHealth Plan, Inc., EmblemHealth Insurance Company, EmblemHealth Services Company, LLC and Health Insurance Plan of Greater New York (HIP) related to health benefit plans offered by these entities. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

### Definitions

The UroLift® system is a minimally invasive implant developed to treat lower urinary tract symptoms (LUTS) related to urinary outflow obstruction secondary to benign prostatic hypertrophy (BPH) in men 50 years of age or older. In this procedure, permanent implants (made from common implantable materials: nitinol, stainless steel and polyethylene terephthalate) are delivered trans-prostatically to retract the enlarged lateral lobes of the prostate. This procedure dilates the prostatic urethra in leading to improvement in LUTS symptoms without the need for surgical resection or the application of thermal energy to the prostate.

### Guideline

Prostatic urethral lift procedures are considered medically necessary when all of the following criteria are met:

1. Symptomatic BPH in male members  $\geq$  45 years of age with well documented voiding symptoms consistent with prostatic hypertrophy
2. Peak urine flow rate ( $Q_{max}$ )  $\leq$  12 cc/sec on a voided volume of  $>$  125 cc
3. Prostate volume  $\leq$  100 cc without an obstructive median lobe
4. No signs, symptoms or diagnostic evidence of active urinary infection and no history of bacterial prostatitis within prior 12-month period

### Limitations/Exclusions

Coverage is for surgical intervention with up to a total of six implants. Implants in excess of six will deny but may be reconsidered on an exception basis with a formal redetermination.

## Revision History

Nov. 12, 2021	Prerequisites removed: <ul style="list-style-type: none"><li>Member has had an adequate trial of, but is refractory to or intolerant of, usual BPH medication</li><li>Normal renal function</li></ul>
Nov. 18, 2020	Prostate volume clarification (80–100 cc changed to ≤ 100 cc)
Oct. 9, 2020	Amended prostate volume criteria (≤ 80 cc changed to 80–100 cc)
Sept. 13, 2019	Lowered age eligibility from 50 to 45 Removed American Urological Association symptom index score prerequisite Removed poor candidacy prerequisite for alternate surgical BPH interventions

## Applicable Procedure Codes

52441	Cystourethroscopy, with insertion of permanent adjustable transprostatic implant; single implant
52442	Cystourethroscopy, with insertion of permanent adjustable transprostatic implant; each additional permanent adjustable transprostatic implant (List separately in addition to code for primary procedure)
C9739	Cystourethroscopy, with insertion of transprostatic implant; 1 to 3
C9740	Cystourethroscopy, with insertion of transprostatic implant; 4 or more implants
L8699	Prosthetic implant, not otherwise specified

## Applicable Diagnosis Codes

N40.1	Enlarged prostate with lower urinary tract symptoms
-------	---

## References

- American Urological Association Guideline: Management of Benign Prostatic Hyperplasia (BPH). Revised 2010.
- Chin PT, Bolton DM, Jack G, et al. Prostatic urethral lift: two-year results after treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. *Urology*. 2012;79(1):5-11.
- Gupta S. L.I.F.T. study: Prostatic urethral lift for the treatment of LUTS associated with BPH. *Indian J Urol*. 2014;30(2):235–236.
- Kaplan S. The prostate urethral lift: will it be uplifting or downgraded as a treatment strategy for benign prostatic hyperplasia? *European Urol*. 2015;67:714–715.
- McNicholas T. Editorial: Going with the flow! Relieving lower urinary tract symptoms and preserving ejaculation. *BJU*. 2014:518-519.
- McNicholas TA, Woo HH, Chin PT, et al. Minimally invasive prostatic urethral lift: surgical technique and multinational experience. *European Urology*. 2013;64:292-299. <http://www.europeanurology.com/article/S0302-2838%2813%2900011-0/abstract/minimally-invasive-prostatic-urethral-lift-surgical-technique-and-multinational-experience>. Accessed November 22, 2021.
- McVary KT, Gange SN, Shore ND, et al. Treatment of LUTS secondary to BPH while preserving sexual function: randomized controlled study of prostatic urethral lift. *J Sex Med*. 2014;11(1):279-287.
- National Institute for Health and Care Excellence (NICE). Insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia. January 2014. <https://www.nice.org.uk/guidance/igp475>. Accessed November 22, 2021.
- National Institute for Health and Care Excellence (NICE). UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia. September 2015. <https://www.nice.org.uk/guidance/mtg26>. Accessed November 22, 2021, 2020.
- Perera M, Roberts MJ, Doi SAR, Bolton D. Prostatic urethral lift improves urinary symptoms and flow while preserving sexual function for men with benign prostatic hyperplasia: a systematic review and meta-analysis. *Eur Urol*. 2015;67:704-713.

- Rees J. Editorial: The prostatic urethral lift: a new treatment for LUTS. *The Practitioner*. 014;258(1767):5.
- Roehrborn CG, Gange SN, Shore ND, et al. Durability of the prostatic urethral Lift: 2-year results of the L.I.F.T. study. *Urology Practice*. 2015;2:1-7.
- Roehrborn CG, Gange SN, Shore ND, et al. The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. Study. *J Urol*. 2013;190(6):2161-2167.
- Roehrborn CG, Rukstalis DB, Barkin J, et al. Three year results of the prostatic urethral L.I.F.T. study. *Canadian Journal of Urology*. 2015;22(3):7772-7782.
- Shore N, Freedman S, Gange S, et al. Prospective multi-center study elucidating patient experience after prostatic urethral lift. *Canadian Journal of Urology*. 2014;21(1):7094-7101.
- Woo HH, Bolton DM, Laborde E, et al. Preservation of sexual function with the prostatic urethral lift: a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. *J Sex Med*. 2012;9:568–575.
- Sonksen J, Barber NJ, Speakman MJ, et al. Prospective, randomized, multinational study of prostatic urethral lift versus transurethral resection of the prostate: 12-month results from the BPH6 study. *Eur Urol*. 2015;68(4):643-652.
- Foster HE, Dahm P, Kohler TS, et al. Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline Amendment 2019. *J Urol*. 2019;202(3):592-598.
- Urolift® Package Insert. [https://f.hubspotusercontent30.net/hubfs/2618738/Brochures/L00181-01\\_RevA\\_UroLift%20System\\_UL400\\_IFU\\_US.pdf](https://f.hubspotusercontent30.net/hubfs/2618738/Brochures/L00181-01_RevA_UroLift%20System_UL400_IFU_US.pdf). Rev Feb 2020. Accessed November 22, 2021.
- Roehrborn CG. Prostatic Urethral Lift: A Unique Minimally Invasive Surgical Treatment of Male Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. *Urol Clin North Am*. 2016;43(3):357-369.
- Roehrborn CG, Barkin J, Gange SN, et al. Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. *Can J Urol*. 2017;24(3):8802-8813.
- Foster HE, Dahm P, Kohler TS, et al. Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline Amendment 2019. *J Urol*. 2019;202(3):592-598.